<code id='ACFD9E8435'></code><style id='ACFD9E8435'></style>
    • <acronym id='ACFD9E8435'></acronym>
      <center id='ACFD9E8435'><center id='ACFD9E8435'><tfoot id='ACFD9E8435'></tfoot></center><abbr id='ACFD9E8435'><dir id='ACFD9E8435'><tfoot id='ACFD9E8435'></tfoot><noframes id='ACFD9E8435'>

    • <optgroup id='ACFD9E8435'><strike id='ACFD9E8435'><sup id='ACFD9E8435'></sup></strike><code id='ACFD9E8435'></code></optgroup>
        1. <b id='ACFD9E8435'><label id='ACFD9E8435'><select id='ACFD9E8435'><dt id='ACFD9E8435'><span id='ACFD9E8435'></span></dt></select></label></b><u id='ACFD9E8435'></u>
          <i id='ACFD9E8435'><strike id='ACFD9E8435'><tt id='ACFD9E8435'><pre id='ACFD9E8435'></pre></tt></strike></i>

          Home / fashion / focus

          focus


          focus

          author:explore    Page View:4
          Adobe

          Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

          In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

          advertisement

          The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In